Evidence map›Paper›PMID 34251052›Full record

ArticleJournal of clinical laboratory analysis2021

Ameliorative effect and mechanism of Yi-Suan-Cha against hyperuricemia in rats.

Yuanyuan Qin, Xuan Zhang, Hui Tao, Yangyang Wu, Jie Yan, Lin Liao, Jianjun Meng, Faquan Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Plantaginis Semen Ameliorates Hyperuricemia Induced by Potassium Oxonate.International journal of molecular sciences · 2024
    Article
  3. Review
  4. Article
  5. Frontiers in nutrition · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuanyuan QinDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xuan ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hui TaoGuangxi Medical College, Nanning, China.
Yangyang WuDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jie YanDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lin LiaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jianjun MengThe First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Faquan LinDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID https://orcid.org/0000-0002-8631-4339
Guangxi Medical University · CN

Funding

Natural Science Foundation of Guangxi Province 2017JJA10152
6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the urate-lowering effects of Yi-Suan-Cha and explore its underlying mechanisms in experimental hyperuricemia induced in rats.

methodsForty-eight male SD rats were randomly allocated into normal control, model, allopurinol, benzbromarone, low-dose Yi-Suan-Cha (0.2 g/ml), and high-dose Yi-Suan-Cha (0.4 g/ml) groups (n = 8 rats per group). Rat models of hyperuricemia were established through intragastric administration of adenine 25 mg/kg + potassium oxalate 300 mg/kg for 3 weeks. After the last administration, serum uric acid, creatinine, and urea nitrogen levels were measured. Renal histopathology was observed by hematoxylin-eosin staining. Xanthine oxidase level in serum and liver homogenates was measured by ELISA. The protein and mRNA expression of URAT1, ABCG2, OAT1, and GLUT9 in the kidney was detected by Western blotting and RT-PCR, respectively.

resultsThe serum uric acid levels were significantly lowered in all medication groups than in the model group. The benzbromarone and both Yi-Suan-Cha groups showed clear kidney structures with no obvious abnormalities. Compared with the normal control group, the model group showed increased URAT1/GLUT9 protein expression and decreased ABCG2/OAT1 protein expression. Compared with the model group, both Yi-Suan-Cha groups showed decreased URAT1/GLUT9 protein expression and increased ABCG2/OAT1 protein expression. Compared with that in the normal control group, URAT1/GLUT9 mRNA expression increased in the model group. Compared with the model group, the low-dose and high-dose Yi-Suan-Cha groups showed decreased URAT1/GLUT9 mRNA expression and increased ABCG2/OAT1 mRNA expression.

conclusionYi-Suan-Cha may lower uric acid level by downregulating URAT1/GLUT9 expression and upregulating ABCG2/OAT1 expression.

Indexed as

AnimalsAnion Transport ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2Blood Urea NitrogenCreatinineDisease Models, AnimalDrugs, Chinese HerbalGene Expression RegulationHyperuricemiaKidneyMaleMonosaccharide Transport ProteinsOrganic Anion Transport Protein 1RatsRats, Sprague-DawleyUric AcidAbcg2 protein, ratAnion Transport ProteinsATP Binding Cassette Transporter, Subfamily G, Member 2CreatinineDrugs, Chinese HerbalGLUT6 protein, ratMonosaccharide Transport ProteinsOrganic Anion Transport Protein 1Slc22a12 protein, ratSlc22a6 protein, ratUric AcidXanthine Oxidasehyperuricemiatransporter proteinuric acidYi-Suan-Cha

Identifiers

PMID34251052
PMCPMC8373314
OpenAlexW3177762725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.